Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into the cancer therapy brands market
• Related reports
• Upcoming related reports

MARKET DEFINITION AND OVERVIEW

• Market definition for this report
  • Antihormonal therapies by ATC class
  • Cytotoxic therapies by ATC class
  • Molecular targeted cancer therapies by ATC class
• Countries and regions included in this report
• Cancer therapy brands included in this report
• Seven major market assessment
  • Current and future market overview
• US market assessment
  • Current and future market overview
• Japan market assessment
  • Current and future market overview
• Five major European market assessment
  • Current and future market overview
• Rest of the World snapshot
  • Current market assessment

BRAND DYNAMICS

• Overview of competitive landscape
  • Seven major markets competitive landscape
  • US competitive landscape
  • Japan competitive landscape
  • Five major European markets competitive landscape
• Leading antihormonal therapy brands
  • Arimidex (anastrozole; AstraZeneca)
  • Lupron (leuprolide; Takeda/Abbott)
• Leading cytotoxic therapy brands
  • Taxotere (docetaxel; Sanofi-Aventis)
  • Eloxatin (oxaliplatin; Sanofi-Aventis)
  • Gemzar (gemcitabine; Eli Lilly)
• Leading molecular targeted therapy brands
  • Avastin (bevacizumab; Genentech/Roche/Chugai)
  • Rituxan (rituximab; Biogen Idec/Genentech/Roche/Chugai/ Zenyaku Kogyo)
  • Herceptin (trastuzumab; Genentech/Roche/Chugai)
  • Gleevec (imatinib; Novartis)
  • Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)

BIBLIOGRAPHY

• Journal papers
• Websites
• Datamonitor reports
• Other

APPENDIX A - MARKET ASSUMPTIONS

• New product launches
• Patent expiries
• Data definitions, limitations and assumptions
  • Standard units
  • Derivation of sales forecasts and pricing trends
• Forecast methodology

APPENDIX B

• Report methodology

TABLES

• Table: Definition of the cancer therapies market by ATC class, 2009
• Table: Drugs included in the Top 20 cancer therapy brands, 2008 and 2018
• Table: Sales and growth of cancer therapy drug classes in the seven major markets, 2008 - 2018
• Table: Key events impacting the cancer therapies market, 2008 - 2018
• Table: Comparison of cancer therapy drug class sales ($m) in the seven major markets and Rest of the World, 2008
• Table: Comparison of cancer therapy sales ($m) in the BRIC countries, Australia and Canada, 2008
• Table: Sales of the Top 20 cancer therapy brands in the seven major markets, 2008
• Table: Forecast sales of the Top 20 cancer therapy brands in 2018 in the seven major markets ($m), 2008 - 2018
• Table: Sales of the Top 20 cancer therapy brands in the US, 2008
• Table: Forecast sales of the Top 20 cancer therapy brands in 2018 in the US ($m), 2008 - 2018
• Table: Sales of the Top 20 cancer therapy brands in Japan, 2008
• Table: Forecast sales of the Top 20 cancer therapy brands in 2018 in Japan ($m), 2008 - 2018
• Table: Sales of the Top 20 cancer therapy brands in the five major EU markets, 2008
• Table: Forecast sales of the Top 20 cancer therapy brands in 2018 in the five major European markets ($m), 2008 - 2018
• Table: Arimidex (anastrozole) - drug profile, 2009
• Table: Impacting factors on the revenues of Arimidex, 2009 - 2018
• Table: Lupron (leuprolide) - drug profile, 2009
• Table: Impacting factors on the revenues of Lupron, 2009 - 2018
• Table: Taxotere - drug profile, 2009
• Table: Impacting factors on the revenues of Taxotere, 2009 - 2018
• Table: Eloxatin - drug profile, 2009
• Table: Impacting factors on the revenues of Eloxatin, 2009 - 2018
• Table: Gemzar - drug profile, 2009
• Table: Impacting factors on the revenues of Gemzar, 2009 - 2018
• Table: Avastin - drug profile, 2009
• Table: Impacting factors on the revenues of Avastin, 2009 - 2018
• Table: Rituxan - drug profile, 2009
• Table: Impacting factors on the revenues of Rituxan, 2009 - 2018
• Table: Herceptin - drug profile, 2009
• Table: Impacting factors on the revenues of Herceptin, 2009 - 2018
• Table: Gleevec - drug profile, 2009
• Table: Impacting factors on the revenues of Gleevec, 2009 - 2018
• Table: Erbitux - drug profile, 2009
• Table: Impacting factors on the revenues of Erbitux, 2009 - 2018
• Table: Datamonitor' s forecast regional launch dates for new cancer therapies in the seven major markets, 2008 - 2018
• Table: Patent expiry dates for approved cancer therapy brands in the seven major markets, 2009 - 2018

FIGURES

• Figure: Cancer therapy sales ($m) in the seven major markets, 2008 - 2018
• Figure: Cancer therapy sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Cancer therapy sales ($m) by class in the seven major markets, 2008 - 2018
• Figure: Sales (by value and volume) of the Top 20 cancer therapy brands versus sales of all other cancer therapies in the seven major markets, 2008 and 2018
• Figure: Sales and market share of the leading 10 cancer therapy brands in the seven major markets, 2008 and 2018
• Figure: Cancer therapy sales ($m) by class in the US, 2008 - 2018
• Figure: Cancer therapy sales ($m) by class in Japan, 2008 - 2018
• Figure: Cancer therapy sales ($m) by class in the five major European markets, 2008 - 2018
• Figure: Rest of the World versus seven major market sales split for sales of cancer therapies ($m), 2008
• Figure: Arimidex SWOT analysis, 2009
• Figure: Arimidex forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Lupron SWOT analysis, 2009
• Figure: Lupron forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Taxotere SWOT analysis, 2009
• Figure: Taxotere forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Eloxatin SWOT analysis, 2009
• Figure: Eloxatin forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Gemzar SWOT analysis, 2009
• Figure: Gemzar forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Avastin SWOT analysis, 2009
• Figure: Avastin forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Rituxan SWOT analysis, 2009
• Figure: Rituxan forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Herceptin SWOT analysis, 2009
• Figure: Herceptin forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Gleevec SWOT analysis, 2009
• Figure: Gleevec forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Erbitux SWOT analysis, 2009
• Figure: Erbitux forecast sales ($m) by country in the seven major markets, 2008 - 2018